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Introduction
In a recent report by Farzadfar et al.1 on global trends in serum total
cholesterol (TC), it is suggested thatHMG-CoA reductase inhibitors
(statins) are important for lowering of average TC in high-income
countries and that statin use is a likely driver of the polarized
trend in average TC seen between low- and high-income countries.
On the other hand, our results show that statins are not a key driver
of lowering of average TC in the Icelandic population observed over
the last decades. This is further supported by findings from USA,2
Scandinavia,3,4 and Czech Republic.5 Where the drop in cardiovas-
cular mortality has been examined, by applying the IMPACT
model, that examines the contribution of changes in various risk
factors and interventions on cardiovascular mortality, the role of re-
duction in cholesterol levels has been demonstrated and largely
shown to be related to other factors than intervention.6–9
The tendency to overestimate the impact of effective pharmaco-
logical intervention on the population cholesterol level calls for an
understanding of which factors have led to the change in popula-
tion TC. This applies to society at large, but especially to policy
makers who need to allocate limited resources in health care
and disease prevention in the most efficient way. Physicians have
an important role to play to share their knowledge in this
context. This is particularly important in the developing countries
where cardiovascular diseases are on an increase.
Cholesterol trend
Total cholesterol levels have lowered considerably in most
Western populations in the last decades.1,2,10,11 This is also the
case in Iceland as shown in Figure 1A and B. Our results are
based on eight cross-sectional studies with individual information
on the cholesterol level and concurrent lipid-lowering medication
during the period of 1967–2008 in males and females, residents of
the Greater Reykjavik area in Iceland (n ¼ 34 237).12 The figure
shows data for individuals not taking lipid-lowering medication
and thus reflects non-pharmacological effect. This entails informa-
tion on the bulk of the population; close to 100% in the years
1967–92, 99.7% in 1993, and 93.3% in 2008. The data show
that the population level of TC has been decreasing since the
mid-1960s, with plateau in the 1980s and steeper fall in the
1990s and the first decade of this century. The drop in population
cholesterol can be seen in all age groups and for both genders. The
drop is parallel in all age groups. Thus, the driving factor behind
these changes affects all generations in the population. These
changes are not driven by pharmacological intervention. The
mean drop in TC in the Icelandic population over four decades
from 1967 to 2008 was 1.5 mmol/L in males and 1.6 mmol/L in
females. This drop in the cholesterol level corresponds well with
0.3 mmol/L decrease per decade since 1980, recently reported
in the Lancet in some other Nordic and European countries. In
their important paper, Farzafar et al.1 estimate the trend in the
mean serum TC in 199 countries in 3.0 million people from
1980 to 2008. Their results show a drop in TC in the high-income
region in the world (0.2 mmol/L per decade) but a slight increase
in Southeast Asia and the Pacific (nearly 0.1 mmol/L per decade).1
Impact of cholesterol changes
The impact of this large decrease in cholesterol on public health is
enormous. In Iceland the mortality rate from coronary heart
disease declined by 80% between 1981 and 2006.13 Of this, 32%
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is attributed to the simultaneous drop in population cholesterol
levels.13 This estimate was based on the well-validated IMPACT
model.6 In addition to cholesterol, other risk factors contributed
to the drop in CHD mortality and this model addresses the con-
tribution of changes in various cardiovascular risk factors and inter-
ventions long known to influence cardiovascular outcomes.
Table 1 gives overview of some of the countries where the
IMPACT model has been applied. The drop in CHD deaths is
50% in developed countries, but an increase of 50% was seen
in males in Beijing, China.14
The change in cholesterol is smallest in England and Wales:
4.2%.7 This drop in the cholesterol level was calculated to have
prevented 9.6% of CHD deaths. The drop in cholesterol was
6.1% in USA8 and 6.2% in Italy15 and 24 and 23% of the lowering
of CHD deaths, respectively, was attributed to this. In Iceland13
and Sweden,16 the lowering in cholesterol is somewhat more pro-
nounced at 14.5 and 10%, respectively, and the attribution to CHD
deaths lowering was 32 and 40%, respectively.
The reverse is seen for Beijing where cholesterol levels have
increased since 1984. This coincides with an alarming 50% increase
in CHD in males in Beijing. This increase in cholesterol was consid-
ered consistent with the changes from a traditional diet to a
Western diet in Beijing.14 Statin use in Beijing in the year 1999
was reported only as secondary prevention after myocardial infarc-
tion. The use was reported 23% in 1999 in Beijing compared with
25% in England and Wales and 36% in the USA in the year 2000.
Effect of statins on population
cholesterol
In the early 1990s, when statins were introduced, the population
average TC was unaffected by statin use. The Icelandic population
average in TC was 5.91 in males and females in the year 1993. In
the year 2008, 4.6% of females and 8.9% of males 25–74 years
of age used statins. For comparison, 7.6% of females and 10.4%
of males aged 25–74 years in Sweden used statins the year 2004 3
and in the same year 11.7% of US population 20 years and older
used statins.17
The average cholesterol level for females in Iceland without
statins in 2008 was 5.11 mmol/L and the population average
(which includes also statin users) was 5.10 mmol/L. The average
cholesterol level for males without statins was 5.18 mm/L and
the population average was 5.10 mmol/L. The fall in TC by statin
use is also shown in Figure 2A and B. The trend for individuals
not using statins is almost superimposable on the population
Figure 1 The age adjusted total cholesterol for individuals not taking lipid-lowering medication (A) men and (B) women from 1967 to 2008 in
three age groups: 25–44 (diamond), 45–64 (boxes), and 65–74 (triangles). The age range in the studies was 25–64 years in 1967 to 1971 and
25–74 years in 1976–2008.
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trend. The steep fall in the mean TC seen in those taking statins
most likely reflects more widespread use of statins in secondary
prevention in patients with relatively normal cholesterol level.
Given on average 30% effect of statins on individual cholesterol
level18 and the above mentioned prevalence of statin use in
2008, it can be estimated that the mean cholesterol level for
24–74 years would have been 5.17 in female instead of 5.10
(0.07 mmol/L lower or 1.3%) and 5.22 in males instead of 5.10
(0.12 mmol/L lower or 2.2%) without statin use. For the age
group 65–74 years old, the prevalence of statin use was 19% in
females and 31% in males in the year 2008 and the effect on popu-
lation cholesterol was 0.28 mmol/L or 4.7% in females and
0.36 mmol/L or 6.8% in males. The effect was negligible in
people younger than 45 years.
This demonstrates again that although statin use is highly effect-
ive in treating individual cholesterol levels and with very beneficial
effect on outcome (for example, increased survival in diabetic
patients treated with statins, recently demonstrated in the same
population19) they are not the main driver of population change
in TC neither in males nor females.
Our results correspond well with results elsewhere. In 2005
Arnett et al.2 published an article on 20 years trends in cholesterol
and medication use between the years 1980–2002 from the Min-
nesota Heart Survey (MHS). Comparison on TC concentration in
the entire MHS population to TC of those not taking lipid-lowering
drugs showed similar results. In the Northern Sweden Monica
study, it was estimated that statin use in the years 1986–2004 con-
tributed to 0.13 mmol/L or 2% lower population TC in people 25–
74 years of age (this was arrived to by estimating on average
1.5 mmol/L decrease in cholesterol concentration in those using
statins and 10.4% prevalence of statin use in men and 7.6% in
women).3 In Finland the effect of lipid-lowering medication in
26–64 years old people was calculated to be 16% in males
and 7% in females or 0.1 mmol/L for the period 1982–2007
(this was arrived to by estimating the effect of statins to be on
average 25% on individual cholesterol levels and 10% prevalence
of statin use in the population).4 In the Czech Republic the choles-
terol levels dropped by 1.1 mmol/L between 1985 and 2007
according to data from the Czech MONICA and Czech post-
MONICA studies.5 Since only 10% of the individuals were
treated with cholesterol-lowering drugs, the change was concluded
to be mainly induced by measures other than pharmacologic.5
Changes in consumption coincide
with lowering cholesterol levels
We suggest that the large fall in cholesterol in Iceland between
1981 and 2008 is driven by major changes in the diet. Food
supply data from the Public Health Institute of Iceland reveal that
the diet in the 1970s was characterized by high consumption of
whole milk and dairy products, stick margarine, butter, lamb,
mutton, and fish. Between 1980 and 2006 there was a considerable
drop in consumption of foods contributing most of the saturated
fatty acid in the diet. Whole milk consumption dropped by 73%,
from 238 kg/person/year to 64 kg, butter decreased by 44% from
3.9 to 2.2 kg/person/year and consumption of margarines made
from hydrogenated fats decreased from 11.7 to 3.2 kg/person/
year; the largest drop occurring in the 1990s, when the most sig-
nificant drop in cholesterol is also seen. Margarine was mainly
replaced by vegetable oils which showed an 88% increase, from
7.6 to 14.3 kg/person/year.
At the same time consumption of the traditional lamb and
mutton decreased by 50% or from 47 to 24 kg/per person/year.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Overview of the impact of population total cholesterol changes in different counties based on publications
where the IMPACT model was used
Gender England and Wales13 USA14 Italy15 Iceland9 Sweden16 Beijing12
Study period (years) Both 1981–2000 1980–2000 1980–2000 1981–2006 1986–2002 1984–1999
Age range Both 25–84 25–84 25–84 25–74 25–84 35–74
CHD deaths per 100 000 at
beginning and end of study period
Male 556214 543267 267141 32468 544253 78109
Female 315173 263134 16179 43188 291140 4666
Change in fatal CHD (direction and %) Male 62 49 47 79 53 50
Female 45 51 51 82 52 27
TC (mmol/L) at beginning and
end of the study period
Both — 5.675.33 5.625.27 6.015.14 6.155.51 4.305.33
Change in population TC (%) Both 4.2 6.1 6.2 14.5 10.4 24.0
Change in CHD death attributed
to change in TC (%)a
Both 9.6 24.2 23.4 31.6 39.5 76.7
Statin use secondary prevention (%)b Both 25 36 44 94 49 23
Statin use primary prevention (%)b Both 3 20 17 4 6 —
aIn the IMPACT papers a regression approach is taken to calculate the numbers of deaths prevented or postponed (NDPP) as a result of a change in risk factor. The formula is
NDPP ¼ [1–exp(coefficient × change in risk factor)] × (expected number of deaths from base year rates), and is applied by sex and within 5-year age groups. The coefficient is a
log-hazard rate of death for 1 unit change in the risk factor. The proportion of deaths prevented which is attributed to the risk factor is then the calculated NDPP for the risk factor
divided by the total number of deaths prevented or postponed due to changes in disease rates’.
bStatin use at the end of the study period.
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The lamb supply has been replaced by other meat products, mainly
poultry and pork. From the 1990s the consumption of total fat in
E% calculated from the food supply statistics has decreased from
40E to 35E%, but the composition of the fat has also changed
from more saturated and trans-fatty acids to cis-unsaturated.
Similar trend in diet can be seen elsewhere. In Finland, consump-
tion of high-fat milk products and butter decreased by 86 and 67%,
respectively, in the period from 1982 to 2007 and consumption of
skimmed milk increased by six-fold.4 The total fat intake in Finland
decreased from nearly 40E% in the late 1960s to close to 30E% in
2007.20
The timing of the largest changes in both diet and cholesterol in
Iceland coincides with the introduction of a national nutrition
policy by the Icelandic government in the year 1987, where the re-
duction in saturated fat was greatly emphasized. Subsequently, the
Icelandic Nutrition Council elaborated this further in Nutrition
recommendations and Nutritional Goals, which had a great influ-
ence on nutrition education and awareness in the country.
However, it is a limitation to not being able to address the effect
of other potentially confounding factors that may have influenced
the changes in cholesterol levels, such as physical activity.
Conclusion
The polarized trend in population TC in high- and low-income
countries, recently described in the report on global trends
lipids,1 is therefore likely to be driven by difference in awareness
about healthy diet and the resulting dietary change rather than
pharmacological intervention.
Our results demonstrate the importance of collaboration
between health scientists, interest groups, and government, and
setting and actively implementing nutritional goals at the popula-
tion level, resulting in a profound impact on the population health.
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Corrigendum to: ‘Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics
and pharmacogenetic data’ [Eur Heart J 2011;32(15):1909-1917, doi:10.1093/eurheartj/ehr116].
Rianne M.F. van Schie, Judith A.M. Wessels, Saskia le Cessie, Anthonius de Boer, Tom Schalekamp, Felix J.M. van der Meer, Talitha
I. Verhoef, Erik van Meegen, Frits R. Rosendaal, and Anke-Hilse Maitland-van der Zee, for the EU-PACT Study Group
This paper was published with a wrong formula. The incorrect formula (1), which is on page 1911, is:
MD = D1 · e
−2k + D2 · e−k + D3
1− e−k
The correct formula is:
MD
1− e−k = D1 · e
−2k + D2 · e−k +D3
The authors apologize for the error.
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